Alnylam Pharmaceuticals(NASDAQ) ALNY

Alnylam helps people with rare and serious diseases by using a natural cell process to stop harmful proteins from being made. The company makes medicines for conditions affecting the heart, nerves, and blood. These treatments target the root causes of illness rather than just managing symptoms.

What is Alnylam Making?

• TTR Franchise: Medicines like AMVUTTRA and ONPATTRO treat a fatal disease called amyloidosis that damages nerves and the heart.
• GIVLAARI: Subcutaneous injection used for adults with acute hepatic porphyria, a rare genetic condition causing life-threatening attacks.
• OXLUMO: Therapy for primary hyperoxaluria type 1, an ultra-rare disease that causes kidney stones and organ damage.
• Leqvio: Cholesterol-lowering medicine developed with Novartis for patients with heart disease or high risk of stroke.
• Qfitlia: Bleeding disorder treatment commercialized by Sanofi to help patients with hemophilia A or B.

Strategic Moves and Partnerships

• Established a global collaboration with Roche in 2023 to co-develop zilebesiran for treating high blood pressure.
• Formed a strategic financing deal with Blackstone in 2020 to fund new drug development and manage royalty payments.
• Collaborated with Regeneron Pharmaceuticals to discover RNA interference treatments for eye and central nervous system diseases.
• Entered a license agreement with PeptiDream in 2021 to find new ways to deliver medicine to tissues outside the liver.

What Makes the Company Unique

Alnylam pioneered the use of RNA interference, a process that silences specific genes to prevent disease-causing proteins from forming. The company owns a large portfolio of patents covering the chemical modifications and delivery tools needed to turn this biological discovery into stable medicines.

Financial Performance Highlights

• Revenue reached $1.1 billion in Q4 2025, up 84.9% from $593.2 million in Q4 2024.
• Net income rose to $186.4 million in Q4 2025, up 322.6% from a loss of $83.8 million in Q4 2024.
• Operating cash flow reached $163.6 million in Q4 2025, up 272.8% year-over-year.
• Free cash flow hit $140.3 million in Q4 2025, up 235.2% from a loss in the previous year.

The Path Forward

Alnylam has transitioned from a research-focused firm to a commercial company with six marketed products. Its focus on genetic validation and new delivery methods for the brain and heart supports its long-term growth strategy.